SUMMARY Growth of the pulmonary arteries was assessed in 11 patients with cyanotic congenital heart disease treated with oral prostaglandin E2. Each patient was dependent on patency of the ductus arteriosus for maintenance of the pulmonary circulation. Measurements were made initially from angiographic data obtained in the neonatal period. Subsequent assessments were made at the time of surgery after an interval of 2-8 months, during which time all the infants had gained weight normally. Comparisons were made with data obtained from 13 normal necropsy specimens. In only 4 of the 11 patients had the pulmonary arteries grown appreciably during the treatment period. In 2 patients no growth occurred, while in 5 patients the pulmonary arteries had actually become smaller. It had been hoped that the pulmonary arteries would grow in all 11 patients during this period, facilitating later surgical intervention. In patients with ductus-dependent cyanotic congenital heart disease, the prolonged use of oral prostaglandin E2 should be restricted to patients in whom the pulmonary arteries are too small to allow a palliative operation to be performed initially.
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Discussion
During the period of this study the policy in this unit has been to treat patients with ductus-dependent pulmonary circulations with oral prostaglandin E2. As the patients themselves continued to grow satisfactorily we had hoped that the pulmonary arteries would do likewise, facilitating later surgical intervention. Unfortunately weight gain was not always associated with pulmonary artery growth. Silove et al.3 reported a study in which prolonged oral prostaglandin treatment was given only to patients in whom the pulmonary arteries were considered too small to attempt a shunt operation initially. In their series there was evidence of pulmonary artery growth in 5 patients, all of whom had very small pulmonary arteries at birth (RMPA 3 mm diameter or less).
We were surprised to find that the RMPA diameter had actually decreased in 5 of our patients. We speculate that the calibre of the ductus had gradually decreased in these patients, despite the use of oral prostaglandin therapy. A progressive reduction in pulmonary perfusion would then have followed. This in turn could have resulted in a gradual decrease in the size of the main branch pulmonary arteries.
A decrease in the diameter of the RMPA might be expected to be associated with an increase in tissue hypoxia which in turn would result in an increase in haemoglobin concentration. In this series no correlation was found between pulmonary artery development and changes in haemoglobin concentration during the same periods of time.
If the RMPA at birth is large enough to offer a reasonable prospect of achieving a technically satisfactory shunt, there is little evidence to suggest that starting oral prostaglandin treatment and postponing surgery improves the long-term outcome. Moreover the institution of prostaglandin therapy often leads to a prolonged time in hospital and to frequent drug administration after discharge. The long-term effects of these highly vaso active agents are as yet poorly defined. In our surgical experience patients thus treated have had a high incidence of tissue friability.
Prostaglandin treatment has contributed greatly to the management of infants with duct-dependent cyanotic congenital heart disease. However, the optimum role of long-term oral prostaglandin E2 in management has yet to be defined. In patients with main branch pulmonary arteries more than 4-5 mm in diameter there is little to be gained by postponing palliative surgery. It is the small group of inoperable patients with main branch pulmonary arteries of less than 3-4 mm diameter that may benefit from longterm oral prostaglandin therapy. Postponing surgery may result in some patients becoming more difficult surgical prospects, as was the case in the 5 patients in our series in whom the RMPA diminished in size. Thus we would advocate that long-term oral prostaglandin therapy be restricted to those patients in whom the small size of the pulmonary arteries precludes early operation. 
